研究成果

[雑誌論文] Bench work for the targeted therapy to the microenvironment of myeloma bone disease

Abe M 2014

[雑誌論文] Defining and targeting myeloma stem cell-like cells

Abe M, Harada T, Matsumoto T 2014

[雑誌論文] Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma

Hiasa M, Jumpei T, Oda A, Amachi R, Harada T, Nakamura S, Miki S, Fujii S, Kagawa K, Watanabe K, Endo I, Kuroda Y, Yoneda T, Tsuji D, Nakao M, Tanaka E, Hamada K, Sano S, Itoh K, Matsumoto T, Abe M 2014

[雑誌論文] Bench work for the targeted therapy to the microenvironment of myeloma bone disease.

Abe M 2014

[雑誌論文] Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.

Harada T, Ozaki S, Oda A, Fujii S, Nakamura S, Miki H, Kagawa K, Takeuchi K, Matsumoto T, Abe M. 2013

[雑誌論文] Serum carboxy-terminal telopeptide of type I collagen (ICTP) as a surrogate marker for vulnerable plaques in atherosclerotic patients: A pilot study

Kato S, Endo I, Fujimura M, Kuriwaka-Kido R, Fujinaka Y, Aihara K, Iwase T, Inoue D, Akaike M, Abe M, Matsumoto T 2013

[雑誌論文] Identification of the risk factors associated with hypocalcemia induced by denosumab.

Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K. 2013

[図書] 骨髄腫Updating第２巻

安倍正博 2013

[雑誌論文] Microenvironment for myeloma growth and drug resistance

Abe M 2013

[雑誌論文] Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients．

Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, and Kizaki M. 2013

[雑誌論文] Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.

Nakamura S, Miki H, Kido S, Nakano A, Hiasa M, Oda A, Amou H, Watanabe K, Harada T, Fujii S, Takeuchi K, Kagawa K, Ozaki S, Matsumoto T, Abe M. 2013

[雑誌論文] Gold nanoparticle cluster-plasmon-enhanced fluorescent silica core-shell nanoparticles for X-ray computed tomography-fluorescence dual-mode imaging of tumors.

Hayashi K, Nakamura M, Miki H, Ozaki S, Abe M, Matsumoto T, Ishimura K. 2013

[雑誌論文] Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment.

Hayashi K, Nakamura M, Sakamoto W, Yogo T, Miki H, Ozaki S, Abe M, Matsumoto T, Ishimura K. 2013

[学会発表] Overview of the pathophysiology of MBD and acquired genetic events: Bench work for the targeted therapy to the microenvironment of MBD

M. Abe 2013

[学会発表] Overview of the pathophysiology of MBD and acquired genetic events: Bench work for the targeted therapy to the microenvironmen of MBD. Session: Myeloma bone disease

M Abe 2013

[学会発表] 骨髄腫骨病変と腫瘍免疫

安倍正博 2013

[学会発表] 骨髄腫骨病変と腫瘍免疫.シンポジウム5骨免疫と炎症性疾患

安倍正博 2013

[雑誌論文] Microenvironment for myeloma growth and drug resistance.

Abe M 2013

[雑誌論文] Serum carboxy-terminal telopeptide of type I collagen (ICTP) as a surrogate marker for vulnerable plaques in atherosclerotic patients: A pilot study.

Kato S, Endo I, Fujimura M, Kuriwaka-Kido R, Fujinaka Y, Aihara K, Iwase T, Inoue D, Akaike M, Abe M, Matsumoto T. 2013

[雑誌論文] 多発性骨髄腫―現状と進歩　骨髄腫の骨病変：骨破壊機序と骨病変に対する標的療法

安倍正博 2012

[学会発表] Multiple myeloma: Topics in basic science applicable to the development of novel therapies

Masahiro Abe 2012

[学会発表] SY6-4 Targeting the interplay between myeloma cells and the bone marrow microenvironment

M Abe 2012

[雑誌論文] TRAIL produced from multiple myeloma cell is associated with osteolytic markers

Kawano Y, Ueno S, Abe M, Kikukawa Y, Yuki H, lyama K, Okuno Y, Mitsuya H, Hata H 2012

[雑誌論文] 骨髄腫の分子病態　造血器腫瘍学―基礎と臨床の最新研究動向―

安倍正博 2012

[学会発表] Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition

Masahiro Abe 2012

[図書] 骨髄腫Updating第１巻

安倍正博 2012

[雑誌論文] Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate

Nakano A, Miki H, Nakamura S, Harada T, Oda A, Amou H, Fujii S, Kagawa K, Takeuchi K, Ozaki 5, Matsumoto T, Abe M 2012

[雑誌論文] 骨免疫学―研究最前線　骨髄腫の骨破壊機序

安倍正博 2012

[雑誌論文] Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL

Kagawa K, Nakano A, Miki H, Oda A, Amou H, Takeuchi K, Nakamura S, Harada T, Fujii S, Yata K, Ozaki S, Matsumoto T, Abe M 2012

[学会発表] An Acidic Milieu Aggravates Myeloma Growth And Drug Resistance But Triggers Anti-myeloma Activity Of Reveromycin A, A Novel Anti-resorptive Agent

Abe M 2011

[雑誌論文] Targeting myeloma-osteoclast interaction with V γ 9V 6 2 T cells

Cui Q, Shibata H, Oda A, Amou H, Nakano A, Yata K, Hiasa M, Watanabe K, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T, Abe M 2011

[雑誌論文] Delayed treatment with vitamin C and N-acetyl-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib

Nakano A, Abe M, Oda A, Amou A, Hiasa M, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, Watanabe T, Ozaki S, Matsumoto T 2011

[雑誌論文] The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, Kagawa K, Endo I, Yata K, Sakai A, Ozaki S, Matsumoto T, Abe M 2011

[雑誌論文] Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents

Abe M 2011

[雑誌論文] KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts

Miki H, Ozaki S, Nakamura S, Oda A, Amou H, Ikegame A, Watanabe K, Hiasa M, Cui Q, Harada T, Fujii S, Nakano A, Kagawa K, Takeuchi K, Yata K, Sakai A, Abe M, Matsumoto T 2011

[雑誌論文] Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma

Abe M 2011